Immune intervention reduces beta-cell death in type 1 diabetes

Immune intervention reduces beta-cell death in type 1 diabetes
Patients recently diagnosed with type 1 diabetes have greater death of pancreatic β-cells compared with patients with long-standing diabetes, which can be reduced by treatment with teplizumab, according to a study published online Feb. 19 in Diabetes.

(HealthDay)—Patients recently diagnosed with type 1 diabetes have greater death of pancreatic β-cells compared with patients with long-standing diabetes, which can be reduced by treatment with teplizumab, according to a study published online Feb. 19 in Diabetes.

Jasmin Lebastchi, from the Yale University School of Medicine in New Haven, Conn., and colleagues compared β- in 43 patients recently diagnosed with , 31 individuals without diabetes, and 37 patients with type 1 diabetes treated with teplizumab or placebo. β-cell death was determined by measuring relative levels of unmethylated INS DNA in serum.

The researchers found that, compared with individuals without diabetes, patients with recent-onset diabetes had higher rates of β-cell death, while patients with long-standing diabetes had lower levels of β-cell death. After treatment of recent-onset with teplizumab, β-cell death was significantly reduced and β-cell function was significantly better preserved.

"Improvement in C-peptide responses with immune intervention is associated with decreased β-cell death," Lebastchi and colleagues write.

Several authors have for teplizumab and/or the assay of unmethylated insulin DNA and are on the scientific advisory board of Islet Sciences.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Cancer prevalence higher with long duration of diabetes

Jan 24, 2013

(HealthDay)—Patients diagnosed with type 2 diabetes have a greater prevalence of cancer with longer diabetes duration and with insulin use, according to a study published online Jan. 8 in Diabetes Care.

Glucose levels at admission predict death in pneumonia

May 30, 2012

(HealthDay) -- For patients with community-acquired pneumonia without preexisting diabetes, serum glucose levels at admission are predictive of death at 28 and 90 days, according to a study published online ...

Turmeric component reduces type 2 diabetes incidence

Jul 12, 2012

(HealthDay) -- A component of turmeric -- curcumin -- reduces the incidence of type 2 diabetes and improves β-cell function in adults with prediabetes, according to a study published online July 6 in ...

Recommended for you

Mechanism behind age-dependent diabetes discovered

Sep 17, 2014

Ageing of insulin-secreting cells is coupled to a progressive decline in signal transduction and insulin release, according to a recent study by researchers at Karolinska Institutet in Sweden. The finding, ...

User comments